XRAY
DENTSPLY SIRONA Inc.
Medical - Instruments & Supplies
Market Cap$2.20B
5Y Perf.-76.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
XRAY vs NVST
Revenue, margins, valuation, and 5-year total return — side by side.
NVST
Envista Holdings Corp
Medical - Equipment & Services
Market Cap$4.04B
5Y Perf.+14.9%
XRAY vs NVST — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | XRAY | NVST |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Equipment & Services |
| Market Cap | $2.20B | $4.04B |
| Revenue (TTM) | $3.68B | $2.81B |
| Net Income (TTM) | $-628M | $68M |
| Gross Margin | 48.9% | 55.1% |
| Operating Margin | 4.1% | 9.0% |
| Forward P/E | 7.7x | 17.2x |
| Total Debt | $2.47B | $1.71B |
| Cash & Equiv. | $326M | $1.21B |
XRAY vs NVST — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
XRAY
NVST
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| DENTSPLY SIRONA Inc. (XRAY) | 100 | 23.6 | -76.4% |
| Envista Holdings Co… (NVST) | 100 | 114.9 | +14.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XRAY vs NVST
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NVST leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DENTSPLY SIRONA Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
XRAY
DENTSPLY SIRONA Inc.
The Value Play
XRAY is the clearest fit if your priority is value and dividends.
- Lower P/E (7.7x vs 17.2x)
- 5.9% yield; 23-year raise streak; the other pay no meaningful dividend
Best for: value and dividends
NVST
Envista Holdings Corp
The Income Pick
NVST carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.65
- Rev growth 8.3%, EPS growth 104.3%, 3Y rev CAGR 1.9%
- -13.1% 10Y total return vs XRAY's -74.5%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NVST | 8.3% revenue growth vs XRAY's -3.0% |
| Value | XRAY | Lower P/E (7.7x vs 17.2x) |
| Quality / Margins | NVST | 2.4% margin vs XRAY's -17.1% |
| Stability / Safety | NVST | Beta 1.65 vs XRAY's 1.78, lower leverage |
| Dividends | XRAY | 5.9% yield; 23-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | NVST | +44.2% vs XRAY's -16.4% |
| Efficiency (ROA) | NVST | 1.2% ROA vs XRAY's -11.2%, ROIC 4.8% vs 5.1% |
XRAY vs NVST — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
FY 2024
XRAY vs NVST — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNVSTLAGGINGXRAY
XRAYDENTSPLY SIRONA Inc.
1leads
NVSTEnvista Holdings Corp
4leads
6 Total Categories
CATEGORYLEADERvs XRAYMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NVST6/6
Valuation MetricsMultiples, price ratios, and targets
XRAY4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NVST7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NVST6/6
Risk & VolatilityBeta, volatility, and downside exposure
NVST2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NVST leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
XRAY and NVST operate at a comparable scale, with $3.7B and $2.8B in trailing revenue. NVST is the more profitable business, keeping 2.4% of every revenue dollar as net income compared to XRAY's -17.1%. On growth, NVST holds the edge at +14.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | XRAYDENTSPLY SIRONA I… | NVSTEnvista Holdings … |
|---|---|---|
| RevenueTrailing 12 months | $3.7B | $2.8B |
| EBITDAEarnings before interest/tax | $424M | $342M |
| Net IncomeAfter-tax profit | -$628M | $68M |
| Free Cash FlowCash after capex | $104M | $220M |
| Gross MarginGross profit ÷ Revenue | +48.9% | +55.1% |
| Operating MarginEBIT ÷ Revenue | +4.1% | +9.0% |
| Net MarginNet income ÷ Revenue | -17.1% | +2.4% |
| FCF MarginFCF ÷ Revenue | +2.8% | +7.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +0.1% | +14.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -150.0% | +130.0% |
NVST leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
XRAY leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, XRAY's 7.2x EV/EBITDA is more attractive than NVST's 13.3x.
| Metric | XRAYDENTSPLY SIRONA I… | NVSTEnvista Holdings … |
|---|---|---|
| Market CapShares × price | $2.2B | $4.0B |
| Enterprise ValueMkt cap + debt − cash | $4.3B | $4.5B |
| Trailing P/EPrice ÷ TTM EPS | -3.65x | 86.73x |
| Forward P/EPrice ÷ next-FY EPS est. | 7.68x | 17.21x |
| PEG RatioP/E ÷ EPS growth rate | — | 58.08x |
| EV / EBITDAEnterprise value multiple | 7.18x | 13.28x |
| Price / SalesMarket cap ÷ Revenue | 0.60x | 1.49x |
| Price / BookPrice ÷ Book value/share | 1.63x | 1.32x |
| Price / FCFMarket cap ÷ FCF | 21.11x | 17.54x |
XRAY leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
NVST leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
NVST delivers a 2.2% return on equity — every $100 of shareholder capital generates $2 in annual profit, vs $-41 for XRAY. NVST carries lower financial leverage with a 0.55x debt-to-equity ratio, signaling a more conservative balance sheet compared to XRAY's 1.84x. On the Piotroski fundamental quality scale (0–9), NVST scores 7/9 vs XRAY's 6/9, reflecting strong financial health.
| Metric | XRAYDENTSPLY SIRONA I… | NVSTEnvista Holdings … |
|---|---|---|
| ROE (TTM)Return on equity | -41.2% | +2.2% |
| ROA (TTM)Return on assets | -11.2% | +1.2% |
| ROICReturn on invested capital | +5.1% | +4.8% |
| ROCEReturn on capital employed | +6.1% | +4.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 |
| Debt / EquityFinancial leverage | 1.84x | 0.55x |
| Net DebtTotal debt minus cash | $2.1B | $496M |
| Cash & Equiv.Liquid assets | $326M | $1.2B |
| Total DebtShort + long-term debt | $2.5B | $1.7B |
| Interest CoverageEBIT ÷ Interest expense | -5.12x | 12.76x |
NVST leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NVST leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NVST five years ago would be worth $5,340 today (with dividends reinvested), compared to $1,991 for XRAY. Over the past 12 months, NVST leads with a +44.2% total return vs XRAY's -16.4%. The 3-year compound annual growth rate (CAGR) favors NVST at -11.3% vs XRAY's -32.6% — a key indicator of consistent wealth creation.
| Metric | XRAYDENTSPLY SIRONA I… | NVSTEnvista Holdings … |
|---|---|---|
| YTD ReturnYear-to-date | -2.8% | +12.0% |
| 1-Year ReturnPast 12 months | -16.4% | +44.2% |
| 3-Year ReturnCumulative with dividends | -69.4% | -30.3% |
| 5-Year ReturnCumulative with dividends | -80.1% | -46.6% |
| 10-Year ReturnCumulative with dividends | -74.5% | -13.1% |
| CAGR (3Y)Annualised 3-year return | -32.6% | -11.3% |
NVST leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
NVST leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NVST is the less volatile stock with a 1.65 beta — it tends to amplify market swings less than XRAY's 1.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVST currently trades 79.8% from its 52-week high vs XRAY's 63.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XRAYDENTSPLY SIRONA I… | NVSTEnvista Holdings … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.78x | 1.65x |
| 52-Week HighHighest price in past year | $17.18 | $30.42 |
| 52-Week LowLowest price in past year | $9.85 | $16.33 |
| % of 52W HighCurrent price vs 52-week peak | +63.8% | +79.8% |
| RSI (14)Momentum oscillator 0–100 | 39.2 | 55.1 |
| Avg Volume (50D)Average daily shares traded | 4.2M | 2.4M |
NVST leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates XRAY as "Hold" and NVST as "Hold". Consensus price targets imply 22.3% upside for XRAY (target: $13) vs 11.2% for NVST (target: $27). XRAY is the only dividend payer here at 5.86% yield — a key consideration for income-focused portfolios.
| Metric | XRAYDENTSPLY SIRONA I… | NVSTEnvista Holdings … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold |
| Price TargetConsensus 12-month target | $13.40 | $27.00 |
| # AnalystsCovering analysts | 31 | 19 |
| Dividend YieldAnnual dividend ÷ price | +5.9% | — |
| Dividend StreakConsecutive years of raises | 23 | — |
| Dividend / ShareAnnual DPS | $0.64 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
NVST leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XRAY leads in 1 (Valuation Metrics).
Best OverallEnvista Holdings Corp (NVST)Leads 4 of 6 categories
Loading custom metrics...
XRAY vs NVST: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is XRAY or NVST a better buy right now?
For growth investors, Envista Holdings Corp (NVST) is the stronger pick with 8.
3% revenue growth year-over-year, versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). Envista Holdings Corp (NVST) offers the better valuation at 86. 7x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate DENTSPLY SIRONA Inc. (XRAY) a "Hold" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — XRAY or NVST?
On forward P/E, DENTSPLY SIRONA Inc.
is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — XRAY or NVST?
Over the past 5 years, Envista Holdings Corp (NVST) delivered a total return of -46.
6%, compared to -80. 1% for DENTSPLY SIRONA Inc. (XRAY). Over 10 years, the gap is even starker: NVST returned -13. 1% versus XRAY's -74. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — XRAY or NVST?
By beta (market sensitivity over 5 years), Envista Holdings Corp (NVST) is the lower-risk stock at 1.
65β versus DENTSPLY SIRONA Inc. 's 1. 78β — meaning XRAY is approximately 8% more volatile than NVST relative to the S&P 500. On balance sheet safety, Envista Holdings Corp (NVST) carries a lower debt/equity ratio of 55% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — XRAY or NVST?
By revenue growth (latest reported year), Envista Holdings Corp (NVST) is pulling ahead at 8.
3% versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). On earnings-per-share growth, the picture is similar: Envista Holdings Corp grew EPS 104. 3% year-over-year, compared to 33. 0% for DENTSPLY SIRONA Inc.. Over a 3-year CAGR, NVST leads at 1. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — XRAY or NVST?
Envista Holdings Corp (NVST) is the more profitable company, earning 1.
7% net margin versus -16. 3% for DENTSPLY SIRONA Inc. — meaning it keeps 1. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVST leads at 8. 3% versus 6. 8% for XRAY. At the gross margin level — before operating expenses — NVST leads at 55. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is XRAY or NVST more undervalued right now?
On forward earnings alone, DENTSPLY SIRONA Inc.
(XRAY) trades at 7. 7x forward P/E versus 17. 2x for Envista Holdings Corp — 9. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XRAY: 22. 3% to $13. 40.
08Which pays a better dividend — XRAY or NVST?
In this comparison, XRAY (5.
9% yield) pays a dividend. NVST does not pay a meaningful dividend and should not be held primarily for income.
09Is XRAY or NVST better for a retirement portfolio?
For long-horizon retirement investors, DENTSPLY SIRONA Inc.
(XRAY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (5. 9% yield). Envista Holdings Corp (NVST) carries a higher beta of 1. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XRAY: -74. 5%, NVST: -13. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between XRAY and NVST?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: XRAY is a small-cap income-oriented stock; NVST is a small-cap quality compounder stock. XRAY pays a dividend while NVST does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(XRAY: 0.1% · NVST: 14.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.